Invention Grant
US09174998B2 (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
有权
（6S，9aS）-N-苄基-6 - [（4-羟基苯基）甲基] -4,7-二氧代-8 - （{6- [3-（哌嗪-1-基）氮杂环丁烷-1-基] -2-基}甲基）-2-（丙-2-烯-1-基） - 八氢-1H-吡嗪并[2,1-c] [1,2,4]三嗪-1-甲酰胺化合物
![(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound](/docs/US/2015-11-03/US09174998B2/abs.jpg.600x600.jpg)
- Patent Title: (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
- Patent Title (中): （6S，9aS）-N-苄基-6 - [（4-羟基苯基）甲基] -4,7-二氧代-8 - （{6- [3-（哌嗪-1-基）氮杂环丁烷-1-基] -2-基}甲基）-2-（丙-2-烯-1-基） - 八氢-1H-吡嗪并[2,1-c] [1,2,4]三嗪-1-甲酰胺化合物
-
Application No.: US14577660Application Date: 2014-12-19
-
Publication No.: US09174998B2Publication Date: 2015-11-03
- Inventor: Satoshi Inoue , Yuji Yamamoto , Kentaro Iso
- Applicant: Eisai R&D Management Co., Ltd. , PRISM Pharma Co., Ltd.
- Applicant Address: JP Tokyo JP Kanagawa
- Assignee: Eisai R&D Management Co., Ltd.,PRISM Pharma Co., Ltd.
- Current Assignee: Eisai R&D Management Co., Ltd.,PRISM Pharma Co., Ltd.
- Current Assignee Address: JP Tokyo JP Kanagawa
- Agency: Fish & Richardson P.C.
- Priority: JPP2013-267687 20131225
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07F9/09 ; C07D401/14 ; A61K31/53 ; A61K35/00
![(6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound](/abs-image/US/2015/11/03/US09174998B2/abs.jpg.150x150.jpg)
Abstract:
A compound represented by formula (1) or pharmaceutically acceptable salt thereof: wherein R1 is a C1-6 alkyl group; R2 and R3 are the same or different from each other and each is a hydrogen atom or a C1-6 alkyl group; X2, X3 and X4 are the same or different from each other and each is a hydrogen atom or a halogen atom; and X5 is a hydrogen atom or —P(═O)(OH)2 has a Wnt Pathway modulating activity.
Public/Granted literature
Information query
